Commentary on the BIT Phase 2 Trial Data, page-336

This is really a question that should be asked in the CYP thread. I think CYP's science is sound, they are just quite early stage compared to MSB which is on the cusp of having a FDA approved product. The last time I looked, CYP had a complicated deal with Fuji which I have no idea how it will turn out and looks risky.

To make this post worthwhile for the BIT investors, the problem in Australia is investors have very unrealistic expectations for how long everything takes. Partly this is due to a lack of money so things progress slower than they should (biotechs here try to do everything on the cheap because they don't have the money), but partly it is just due to the nature of biotech. This investor bias makes early stage biotechs relatively expensive and late stage relatively cheap for the time weighted risk.

For those who are wondering BIT is early stage (preclinical) now that BIT225 is dead.